Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib EAP in Advanced RCC
NCT00478114Phase 3Completed
- Sponsor
- Mahidol University
- Start
- May 2007
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sorafenib in renal cell carcinoma (RCC), sponsored by Mahidol University. Primary endpoints: Time to Progression at 2 years and Progression Free Survival at 2 years. Started May 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00478114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00478114.